ArticleHaematologica2017

Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.

Patrice Chevallier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.